体外膜氧合患者的抗凝策略:网络Meta分析与系统评价
该网络Meta分析纳入23项试验共2522例ECMO患者,比较普通肝素、阿加曲班、比伐卢定和甲磺酸萘莫司他的抗凝效果。比伐卢定较普通肝素降低器械相关和患者相关血栓风险,甲磺酸萘莫司他降低院内死亡风险,但各替代药物与普通肝素在大出血风险上无显著差异。
要点
- 比伐卢定较普通肝素降低器械相关血栓(OR 0.51)和患者相关血栓(OR 0.44)风险。
- 甲磺酸萘莫司他较普通肝素降低院内死亡风险(OR 0.27)。
- 三种替代药物与普通肝素在大出血风险上均无显著差异。
核心结论
- 与普通肝素和阿加曲班相比,比伐卢定降低血栓风险,可能是ECMO患者更优选择。
- 甲磺酸萘莫司他与降低院内死亡风险相关。
研究设计与样本
- 网络Meta分析与系统评价,检索MEDLINE、Embase、Web of Science和Cochrane Central Register of Controlled Trials至2023年1月31日。
- 纳入23项试验共2522例接受ECMO的患者,比较普通肝素、阿加曲班、比伐卢定和/或甲磺酸萘莫司他。
主要发现
- 比伐卢定较普通肝素降低器械相关血栓风险(OR 0.51,95%CI 0.33-0.84)。
- 比伐卢定较普通肝素降低患者相关血栓风险(OR 0.44,95%CI 0.18-0.85)。
- 甲磺酸萘莫司他较普通肝素降低院内死亡风险(OR 0.27,95%CI 0.091-0.77)。
- 三种替代药物与普通肝素在大出血风险上无显著差异:比伐卢定(OR 0.54,95%CI 0.23-1.3)、阿加曲班(OR 1.3,95%CI 0.34-5.8)、甲磺酸萘莫司他(OR 0.60,95%CI 0.13-2.6)。
临床怎么用
- 对于ECMO患者,比伐卢定可作为优先考虑的抗凝药物以降低血栓风险。
- 甲磺酸萘莫司他可能有助于降低院内死亡风险,但需结合患者具体情况选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Extracorporeal membrane oxygenation (ECMO) plays an important role in providing temporary life support for patients with severe cardiac or pulmonary failure, but requires strict anticoagulation and monitoring. This network meta-analysis systematically explored the most effective anticoagulation and monitoring strategies for patients receiving ECMO. METHODS: MEDLINE, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were searched up to January 31, 2023, for studies comparing unfractionated heparin (UFH), argatroban (Arg), bivalirudin (Biv), and/or nafamostat mesylate (NM) in patients receiving ECMO. The primary outcomes included device-related thrombosis, patient-related thrombosis, and major bleeding events. The secondary outcomes included ECMO survival, ECMO duration, and in-hospital mortality. RESULTS: A total of 2522 patients from 23 trials were included in the study. Biv was associated with a decreased risk of device-related thrombosis (odd ratio [OR] 0.51, 95% confidence interval [CI]: 0.33-0.84) compared with UFH, whereas NM (OR 2.2, 95% CI: 0.24-65.0) and Arg (OR 0.92, 95% CI: 0.43-2.0) did not reduce the risk of device-related thrombosis compared with UFH. Biv was superior to Arg in decreasing the risk of device-related thrombosis (OR 0.14, 95% CI: 0.03-0.51). Biv reduced the risk of patient-related thrombosis compared with UFH (OR 0.44, 95% CI: 0.18-0.85); NM (OR 0.65, 95% CI: 0.14-3.3) and Arg (OR 3.1, 95% CI: 0.94-12.0) did not decrease risk of patient-related thrombosis compared with UFH. No significant difference was observed in the risk of major bleeding between three alternatives and UFH: Biv (OR 0.54, 95% CI: 0.23-1.3), Arg (OR 1.3, 95% CI: 0.34-5.8), and NM (OR 0.60, 95% CI: 0.13-2.6). NM showed a reduced risk of in-hospital mortality compared with UFH (OR 0.27, 95% CI: 0.091-0.77), whereas Arg (OR 0.43, 95% CI: 0.15-1.2) and Biv (OR 0.75, 95% CI: 0.52-1.1) did not decrease risk of in-hospital mortality. CONCLUSIONS: Compared with UFH and Arg, Biv reduces the risk of thrombosis and appears to be a better choice for patients requiring ECMO. NM was associated with a reduced risk of in-hospital mortality.
引用
- Chen J, Chen G, Zhao W, et al. Anticoagulation strategies in patients with extracorporeal membrane oxygenation: A network meta-analysis and systematic review. Pharmacotherapy. 2023. PMID: 37538041. doi:10.1002/phar.2859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。